Litigation Details for Galderma Laboratories, L.P. v. Actavis Mid Atlantic LLC (N.D. Tex. 2012)

Galderma Laboratories, L.P. v. Actavis Mid Atlantic LLC (N.D. Tex. 2012)

Docket		Date Filed	2012-06-26
Court	District Court, N.D. Texas	Date Terminated	2015-04-11
Cause	35:271 Patent Infringement	Assigned To	James E. Kinkeade
Jury Demand		Referred To
Parties	ACTAVIS MID ATLANTIC LLC
Patents	7,820,186; 8,071,644; 8,080,537; 8,129,362; 8,445,543
Link to Docket	External link to docket

Details for Galderma Laboratories, L.P. v. Actavis Mid Atlantic LLC (N.D. Tex. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-06-26				External link to document

Galderma Laboratories v. Actavis Mid Atlantic: Litigation Summary and Patent Analysis

Last updated: August 3, 2026

Galderma Laboratories, L.P. v. Actavis Mid Atlantic LLC, No. 3:12-cv-02038, was a Hatch-Waxman patent case involving Actavis’ abbreviated new drug application for a generic version of Oracea, Galderma’s 40 mg doxycycline capsule for the treatment of inflammatory lesions associated with rosacea. Galderma asserted Oracea-related patents after receiving Actavis’ Paragraph IV certification. The case was resolved without a publicly reported trial judgment establishing patent validity or infringement.

What drug and patents were involved in Galderma v. Actavis?

The product at issue was Oracea, a once-daily 40 mg doxycycline capsule. Oracea uses a subantimicrobial dose of doxycycline designed to treat rosacea inflammation without producing the antibiotic exposure associated with conventional doxycycline dosing.

Item	Details
Branded product	Oracea
Active ingredient	Doxycycline
Dosage form	Delayed-release capsule
Strength	40 mg
Regulatory pathway	ANDA litigation under the Hatch-Waxman Act
Plaintiff	Galderma Laboratories, L.P.
Defendant	Actavis Mid Atlantic LLC
Court	U.S. District Court for the Northern District of Texas
Case number	3:12-cv-02038
Principal patent subject	Subantimicrobial doxycycline treatment and controlled-release delivery

The asserted patent estate included patents associated with Oracea’s low-dose doxycycline regimen and delivery profile. Publicly identified Oracea patents include U.S. Patent Nos. 7,211,267, 7,232,572, and 8,206,740. The precise patent claims and asserted claims must be read against the operative pleadings and docket filings because Hatch-Waxman complaints often assert only selected claims from a broader Orange Book-listed estate.

U.S. Patent No. 7,211,267

Patent No. 7,211,267 generally covers methods for treating rosacea using a subantimicrobial dose of doxycycline. The commercial significance of the patent is its focus on the therapeutic use of low-dose doxycycline rather than on conventional antibiotic treatment.

The patent’s scope creates a typical method-of-use challenge. An ANDA applicant may seek to avoid infringement through a “skinny label” that omits the patented indication. That strategy is more difficult where the product’s approved labeling and commercial use remain closely linked to the patented rosacea treatment.

U.S. Patent No. 7,232,572

Patent No. 7,232,572 is associated with controlled-release doxycycline compositions. Its relevance is the formulation and release profile required to deliver doxycycline in a manner consistent with Oracea’s subantimicrobial product design.

Formulation claims can create a stronger barrier than method-of-use claims when the generic product must use substantially the same release architecture to satisfy the FDA’s bioequivalence requirements. Their strength depends on claim construction, the specific ANDA formulation, and whether the asserted claims require structural features that can be designed around.

U.S. Patent No. 8,206,740

Patent No. 8,206,740 is another Oracea-related patent concerning doxycycline compositions and methods. Because it issued after earlier Oracea patents, it expanded or continued the patent protection surrounding the product’s composition and clinical use.

The relevance of this patent to the Actavis case depends on whether Galderma asserted it in the operative complaint or amended pleadings. Patent issuance alone does not establish that every listed Oracea patent was litigated in the case.

When did the Oracea patents expire?

The principal Oracea patents trace back to early-2000s applications and generally carried expiration dates in 2022, subject to patent-term adjustment and pediatric exclusivity.

Patent	General subject	Approximate base expiration	Potential pediatric extension
7,211,267	Low-dose doxycycline treatment of rosacea	2022	Potentially extended by six months
7,232,572	Controlled-release doxycycline composition	2022	Potentially extended by six months
8,206,740	Doxycycline compositions and methods	2022	Dependent on applicable term calculation

The exact enforceable expiration date is determined by the patent term recorded by the USPTO, including any patent-term adjustment, terminal disclaimer, or pediatric exclusivity. The effective commercial barrier has since expired, eliminating the principal patent-based obstacle to generic Oracea entry.

What was the procedural history of Galderma v. Actavis?

Galderma filed the action in 2012 after Actavis challenged Oracea-related patent protection in connection with its ANDA. The case followed the standard Hatch-Waxman sequence:

1. Actavis submitted an ANDA for a generic doxycycline product.
2. Actavis provided a Paragraph IV certification challenging one or more Orange Book-listed patents.
3. Galderma filed suit within the statutory 45-day period.
4. The litigation triggered the statutory 30-month stay of FDA approval, unless the stay was shortened, terminated, or otherwise affected by court action.
5. The parties resolved the dispute without a reported merits judgment.

The docket identifies the dispute as a patent infringement action under the Hatch-Waxman framework. The publicly reported record does not establish a trial verdict holding the asserted patents valid and infringed.

Was there a Paragraph IV challenge to Oracea?

Yes. The litigation was initiated in response to Actavis’ ANDA-related patent certifications. That structure indicates a Paragraph IV challenge to Oracea patent protection.

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. It does not itself invalidate the patent. The patent holder must obtain a judicial ruling or settlement-based resolution before the generic can proceed under the applicable regulatory framework.

The Actavis case therefore represented an early generic challenge to Galderma’s Oracea franchise. It did not produce a publicly reported claim-construction or invalidity ruling that would have materially narrowed the broader Oracea patent estate.

Did the court decide whether the Oracea patents were valid?

No publicly reported final merits decision appears to have determined that the asserted Oracea patents were valid and infringed by Actavis.

The case was resolved through a negotiated disposition rather than a reported trial judgment. As a result:

• The court did not issue a precedential ruling confirming the full scope of the asserted claims.
• The record does not establish a judicial finding of patent invalidity.
• The settlement terms did not publicly disclose the commercial launch date agreed between the parties.
• The litigation did not create binding Federal Circuit precedent on Oracea claim construction.

This distinction matters for later challengers. A settlement may preserve the commercial value of the patent estate for the brand company, but it does not provide the same litigation precedent as a judgment after trial.

What was the settlement and generic launch outcome?

The case ended without a publicly reported trial judgment. The settlement agreement appears to have been confidential or only partially disclosed in the public record. The available docket history does not provide a complete public account of the agreed generic launch date, royalty structure, or licensing terms.

The commercial effect was to defer an immediate Actavis launch while preserving Galderma’s ability to commercialize Oracea during the remaining patent term. Once the relevant patent and regulatory barriers expired, generic entry became possible without the same litigation risk.

Because the agreement terms were not fully public, the following issues cannot be treated as established facts from the docket alone:

• Whether Actavis received an authorized-generic license.
• Whether Actavis agreed to a specific launch date.
• Whether Galderma paid or received consideration.
• Whether the settlement included supply, co-promotion, or manufacturing provisions.
• Whether the agreement imposed restrictions beyond the listed patents.

What was the FDA and Orange Book status of Oracea?

Oracea was approved by the FDA as a 40 mg doxycycline capsule for the treatment of inflammatory lesions associated with rosacea. The product’s regulatory differentiation rests on its subantimicrobial dosing and delayed-release design.

The FDA Orange Book listed patents associated with the product’s approved drug substance, formulation, and method of use. Those listings gave Galderma the basis to receive Paragraph IV notices and to file Hatch-Waxman litigation.

The principal regulatory barriers were separate from patent protection:

Regulatory protection	Relevance to Oracea
New drug application approval	Established the reference listed drug
Orange Book listings	Identified patents that could trigger ANDA litigation
30-month stay	Delayed FDA approval after timely patent litigation
Pediatric exclusivity	Could extend listed patent protection by six months
Orphan exclusivity	Not the principal protection at issue in this case

The relevant patents have expired. Generic applicants therefore face substantially lower patent risk than applicants did when Actavis filed its ANDA challenge.

How strong was Galderma’s Oracea patent estate?

The estate had moderate-to-strong historical value but mixed litigation durability.

Strengths

The patents covered more than one aspect of Oracea:

• The therapeutic use of subantimicrobial doxycycline.
• The controlled-release formulation.
• The composition and administration of the product.
• The commercial product’s clinically important low-dose profile.

This layered structure increased the likelihood that an ANDA applicant would need to address multiple patent theories rather than defeat a single compound patent.

Weaknesses

The estate also had predictable vulnerabilities:

• Method-of-use claims can be challenged through label carve-outs.
• Formulation claims may be vulnerable to noninfringement arguments based on release characteristics.
• Low-dose doxycycline claims can face prior-art arguments involving tetracycline treatment of rosacea.
• The patents did not provide a new chemical entity exclusivity barrier comparable to a compound patent.
• The estate was approaching expiration when the Actavis litigation was filed.

The most commercially important protection was likely the combination of the approved indication and formulation requirements. The absence of a strong composition-of-matter patent reduced the long-term durability of the franchise.

What generic entry risks existed for Oracea?

At the time of the Actavis filing, generic entry risk was material but manageable for Galderma.

Risk factor	Assessment
Patent challenge	High, because Actavis filed a Paragraph IV challenge
Immediate launch risk	Limited by the litigation-triggered approval stay
Method-of-use design-around	Potentially available through labeling changes
Formulation design-around	More difficult if bioequivalence required the same release profile
Settlement risk	Material because the patent term was finite
Post-expiration entry	High once patent and exclusivity barriers ended
Biosimilar risk	None; Oracea is a small-molecule drug
Authorized generic risk	Dependent on confidential settlement and commercial arrangements

Oracea did not face biosimilar competition because doxycycline is a small-molecule active ingredient regulated through the ANDA pathway. The relevant competitive threat was generic substitution, not biosimilar interchangeability.

Which companies challenged Oracea patent protection?

Actavis was one of the early ANDA challengers identified in the Oracea patent litigation record. Other generic companies later pursued or litigated related Oracea patents, including companies such as Mylan, Amneal, and Teva in separate proceedings or regulatory challenges involving the broader Oracea patent estate.

Those proceedings should not be treated as part of No. 3:12-cv-02038. They may involve different ANDAs, different asserted patents, different formulations, and different settlement terms.

What is the current commercial significance of the case?

The case is most significant as an example of early generic pressure against a branded low-dose doxycycline product protected by method-of-use and formulation patents rather than by a durable composition-of-matter patent.

For Galderma, the settlement protected the remaining commercial life of Oracea without requiring a public trial. For Actavis, the filing preserved an opportunity to reach the market after the agreed restrictions or patent term ended. For later generic applicants, the absence of a merits ruling reduced the precedential value of the case.

The relevant business conclusions are:

• The product had a layered but time-limited patent estate.
• The case did not establish a definitive judicial validation of Oracea patents.
• The settlement likely reduced near-term launch uncertainty for Galderma.
• Generic entry became commercially viable after patent expiration.
• The case has no biosimilar component.
• Manufacturing and formulation know-how could still affect market entry, but those barriers are weaker than an unexpired patent or regulatory exclusivity period.

Key Takeaways

• Galderma Laboratories v. Actavis Mid Atlantic, No. 3:12-cv-02038, was a Hatch-Waxman action involving generic Oracea.
• The dispute concerned 40 mg doxycycline capsules and patents covering subantimicrobial rosacea treatment and controlled-release delivery.
• Galderma responded to Actavis’ Paragraph IV challenge by filing patent litigation in the Northern District of Texas.
• The case ended without a publicly reported trial judgment on validity or infringement.
• The settlement terms and agreed launch date were not fully disclosed publicly.
• Oracea’s principal patent protection generally expired in 2022, subject to applicable extensions and term adjustments.
• Generic entry risk is now primarily commercial and regulatory rather than based on the original patent dispute.
• Biosimilar risk is not relevant because doxycycline is a small-molecule drug.

FAQs About Galderma v. Actavis and Oracea Patent Litigation

What was Actavis seeking approval to market?

Actavis sought FDA approval for an ANDA product intended to compete with Oracea, Galderma’s 40 mg doxycycline delayed-release capsule for rosacea.

Did Actavis win the Oracea patent case?

The public record does not show a merits victory for Actavis. The case was resolved without a reported trial judgment determining that the asserted patents were invalid or not infringed.

Did Galderma obtain an injunction against Actavis?

The public disposition does not establish a permanent injunction following a merits decision. The principal delay mechanism was the Hatch-Waxman regulatory stay associated with the patent litigation.

Are the Oracea patents still enforceable?

The principal Oracea patents associated with the litigation generally reached expiration in 2022, subject to any recorded patent-term adjustment or pediatric extension. Current enforcement must be assessed against the individual patent’s recorded expiration data.

Can a generic company use a different doxycycline formulation?

Potentially. A generic applicant may pursue a formulation that avoids asserted formulation claims, but it must still satisfy FDA requirements for pharmaceutical equivalence, bioequivalence, quality, and labeling under the ANDA pathway.

References

1. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: The Orange Book. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. Galderma Laboratories, L.P. v. Actavis Mid Atlantic LLC, No. 3:12-cv-02038, U.S. District Court for the Northern District of Texas.

3. U.S. Patent No. 7,211,267. (2007). Methods of treating rosacea. U.S. Patent and Trademark Office.

4. U.S. Patent No. 7,232,572. (2007). Controlled release doxycycline compositions. U.S. Patent and Trademark Office.

5. U.S. Patent No. 8,206,740. (2012). Doxycycline compositions and methods. U.S. Patent and Trademark Office.

6. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda.